Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint by Ciborowski, Michał et al.
Metabolomics with LC-QTOF-MS Permits the Prediction
of Disease Stage in Aortic Abdominal Aneurysm Based
on Plasma Metabolic Fingerprint
Michal Ciborowski1,2, Joanna Teul1,3, Jose Luis Martin-Ventura4,5, Jesu´s Egido4,5, Coral Barbas1*
1CEMBIO (Center for Metabolomics and Bioanalysis), Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain, 2Department of Physical Chemistry, Medical
University of Bialystok, Bialystok, Poland, 3Department of Pharmaceutical Analysis, Medical University of Bialystok, Bialystok, Poland, 4 Vascular Research Laboratory, IIS-
Fundacio´n Jime´nez Dı´az, Madrid, Spain, 5Auto´noma University, Madrid, Spain
Abstract
Abdominal aortic aneurysm (AAA) is a permanent and localized aortic dilation, defined as aortic diameter $3 cm. It is an
asymptomatic but potentially fatal condition because progressive enlargement of the abdominal aorta is spontaneously
evolving towards rupture. Biomarkers may help to explain pathological processes of AAA expansion, and allow us to find
novel therapeutic strategies or to determine the efficiency of current therapies. Metabolomics seems to be a good approach
to find biomarkers of AAA. In this study, plasma samples of patients with large AAA, small AAA, and controls were
fingerprinted with LC-QTOF-MS. Statistical analysis was used to compare metabolic fingerprints and select metabolites that
showed a significant change. Results presented here reveal that LC-QTOF-MS based fingerprinting of plasma from AAA
patients is a very good technique to distinguish small AAA, large AAA, and controls. With the use of validated PLS-DA
models it was possible to classify patients according to the disease stage and predict properly the stage of additional AAA
patients. Identified metabolites indicate a role for sphingolipids, lysophospholipids, cholesterol metabolites, and
acylcarnitines in the development and progression of AAA. Moreover, guanidinosuccinic acid, which mimics nitric oxide
in terms of its vasodilatory action, was found as a strong marker of large AAA.
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Introduction
Abdominal aortic aneurysm (AAA) is a permanent and localized
aortic dilation, defined as aortic diameter $3 cm. Its development
is connected with oxidative stress, chronic aortic wall inflamma-
tion, elastin fragmentation, apoptosis and loss of extracellular
matrix, neovascularization, and depletion of smooth muscle cells
(SMC) [1,2]. It is an asymptomatic but potentially fatal condition
because progressive enlargement of the abdominal aorta is
spontaneously evolving towards rupture [3].
Based on the population screening studies prevalence rates of
AAA vary according to age, gender and geographical location [4].
Although it is hypothesized that the incidence of AAAs has begun
to fall in Australia and that the admission rate for aneurysm repair
was observed to decline in USA [5], ruptured AAAs are still
responsible for at least 15000 deaths in the USA each year [6].
Efforts to limit the mortality rate from ruptured AAA depend on
AAA early detection and elective repair. The indication for
elective repair, based on large-scale randomized trials, is AAA size
above 5.5 cm in diameter [7]. Survival of patients with small AAA
(,5.5 cm in diameter) was not improved by elective surgical
repair, additionally there is currently no well-defined treatment
strategy for them [1]. There were studies evaluating the value of
statins [8], b-blockers, antibiotics or antiplatelet therapy in
reducing AAA progression but further investigations are necessary
in this area [6].
Currently aortic imaging methods such as ultrasound (US),
magnetic resonance imaging (MRI) and computed tomography
(CT) are valid, suitable, and acceptable methods for AAA
diagnosis. However, the benefit of early diagnosis of AAA was
limited, because 90% of aneurysms detected by these methods
were below the currently accepted threshold for surgical
intervention. Moreover, small AAAs do rupture occasionally,
therefore, if it could be possible to predict which small AAAs most
likely require surgical intervention, intervention could perhaps be
offered earlier with less morbidity and mortality [6]. Thus,
biomarkers may help to explain pathological processes of AAA
expansion, and also allow finding novel therapeutic strategies or
determining the efficiency of current therapies. The development
of novel high-throughput technologies (e.g. genomics/proteomics/
metabolomics) could help in the search of novel biomarkers.
Genome wide linkage analysis and candidate gene analysis has
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been performed in AAA patients [9]. Genetic biomarkers
provide insights in disease susceptibility, but the information
provided is static. Proteomic studies have been recently applied
to AAA tissue and plasma samples [10,11]. Interestingly, one of
the identified biomarkers in one of these studies, peroxiredoxin-
1, was associated to AAA presence, size and growth. More
importantly, peroxiredoxin-1 quantification provided significant-
ly additive value in predicting AAA growth when combined
with AAA size [10]. This data highlights the dynamic and
clinical usefulness of proteomic studies in the identification of
novel biomarkers of AAA.
Metabolomics combining sensitive analytical techniques with
multivariate analysis seems to be a good approach to find
biomarkers of AAA. One of the approaches of metabolomics is
metabolic fingerprinting, which looks into a total profile, or
fingerprint, as a unique pattern characterizing metabolism in a
particular case [12]. It was reported previously that this
methodology can be applied to the differential analysis of
metabolites released by normal and pathological arteries as well
as intraluminal thrombus (ILT) into culture medium resulting in
the successful identification of compounds related to inflammation
and oxidative stress [13]. These compounds could have a high
probability of later being found in plasma and be useful
diagnostic/prognostic biomarkers.
In the present study, plasma samples of patients with large AAA,
small AAA, and controls with high-performance liquid chroma-
tography quadrupole time-of-flight tandem mass spectrometry
(LC-QTOF-MS) were fingerprinted. The main adventages of this
technique are high sensitivity and good potential for biomarker
identification. The broad applicability of LC-QTOF-MS to
metabolites of all classes justified the choice for the problem
under consideration.
Materials and Methods
Ethics statement
Patients and controls were recruited in the Fundacio´n Jimenez
Diaz Hospital with the approval of the Ethics Committee at the
Fundacio´n Jimenez Diaz Hospital. Written informed consent from
all participants involved in the study was obtained.
Blood Collection and Sample Preparation
Blood was collected from two groups of patients with previously
diagnosed abdominal aortic aneurysm: small aneurysm (S)
(AAA,5 cm) n= 15 and large aneurysm (A) (AAA.5 cm)
n= 15, and from healthy subjects (C) n= 11. Characteristics of
study participants are presented in Table 1. For data modeling
only 11 samples per group were used in such a way that
individuals were matched in age and sex (7169, 7764, and 7367
years for A, S, and C respectively). Additionally plasma samples
from 8 AAA patients (4 from A group and 4 from S) who were not
matched in age to the other patients in their groups (significantly
different according to Mann–Whitney U test, p-value = 0.015 in
both comparisons) were also analysed and used for prediction. The
range of age of those additional patients was 58–59 years for group
A and 85–88 years for S. Thus, in total, plasma samples of 41
humans were investigated.
All subjects were in a fasting state, and blood samples were
taken in the morning (between 8 h00 and 11 h00). Fresh EDTA
anti-coagulated blood was centrifuged at 10006g for 10 min at
4uC. Plasma was stored in aliquots at 280uC until the day of
analysis.
Protein precipitation and metabolite extraction was performed
by adding 1 volume of plasma to 3 volumes of cold (220uC)
mixture of methanol and ethanol (1:1). Samples were then vortex-
mixed and stored at 220uC for 5 min. The pellet was removed by
centrifuging at 16 0006g for 10 min at 4uC, and the supernatant
was filtered through a 0.22 mm nylon filter.
Due to the small volume of plasma available in the study,
Quality Control (QC) samples (n = 13) were not prepared by
pooling an aliquot of them, as in previous studies, but from a pool
of human plasma obtained from healthy volunteers that was
available in the laboratory. Each QC sample was prepared
independently from this pooled plasma following the same
procedure as for the rest of samples, and analyzed only once.
QCs were injected at the beginning of the run and after every 3–4
real samples to provide a measurement not only of the system’s
stability and performance [14] but also of the reproducibility of the
sample treatment procedure.
Metabolic Fingerprinting with ESI-QTOF-MS
The HPLC system consisted of a degasser, two binary pumps,
and thermostated autosampler, maintained at 4uC (1200 series,
Agilent); 10 mL of extracted plasma sample was applied to a
reversed-phase column (Discovery HS C18 15 cm62.1 mm, 3 mm;
Supelco) with a guard column (Discovery HS C18 2 cm62.1 mm,
3 mm; Supelco) thermostated at 40uC. The system was operated in
positive ion mode at the flow rate 0.6 mL/min with solvent A -
water with 0.1% formic acid, and solvent B - acetonitrile with
0.1% formic acid. The gradient started from 25% B to 95% B in
35 min, and returned to starting conditions in 1 min, keeping the
re-equilibration at 25% B for 9 min. Data were collected in
positive ESI mode in separate runs on a QTOF (Agilent 6520)
operated in full scan mode from 50 to 1000 m/z. During the
analysis two reference masses: 121.0509 m/z (C5H4N4) and
922.0098 m/z (C18H18O6N3P3F24) were continuously measured
to allow constant mass correction, and obtain the accurate mass.
The capillary voltage was 3000 V with a scan rate of 1.02 scan per
second; the nebulizer gas flow rate was 10.5 L/min. Samples were
analyzed in one randomized run.
Table 1. Characteristics of study participants.
Group Hypertension Diabetes Dyslipidemia Cardiopathy COPD Statins ILT
Control 10 5 7 3 1 8 0
Small AAA 8 5 6 3 2 4 0
Large AAA 6 1 7 1 2 4 6
COPD – chronic obstructive pulmonary disease.
ILT – intraluminal thrombus.
doi:10.1371/journal.pone.0031982.t001
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Data treatment
The resulting data file was cleaned of back-ground noise and
unrelated ions by the Molecular Feature Extraction (MFE) tool
in the Mass Hunter Qualitative Analysis Software (Agilent). The
MFE then created a list of all possible components as
represented by the full TOF mass spectral data. Exact mass
databases quoted below were then searched for hits to identify
the compounds.
Primary data treatment (filtering and alignment) was per-
formed with Mass Profiler Professional B.02.00 (Agilent) software.
Further data treatment was performed by using MS Excel
(Microsoft). Data were transformed by applying common
logarithm to intensities in order to approximate a normal
distribution. The normality of distribution was assessed using
the Wilk-Shapiro test. Differences between plasma metabolites in
all comparisons (C vs A, C vs S, and A vs S) were evaluated for
individual metabolites by using a t test. Unequal variance
(Welch’s t test) was assumed. Accurate masses of features
representing significant differences were searched against the
METLIN, KEGG, LIPIDMAPS and HMDB databases.
SIMCA-P+ 12.0 (Umetrics) was used for multivariate statistical
calculations and plotting.
To discriminate the samples between the groups and allocate
new objects in the model obtained, partial least square
discriminant analysis (PLS-DA) method was used. In addition, to
avoid the risk of overfitting, models were validated by cross-
validation tool [15].
Compound identification
The identity of compounds that were found to be significant in
class separation (Tables 2, 3, and 4) was confirmed by LC-MS/MS
by using a QTOF (model 6520, Agilent). Experiments were
repeated with identical chromatographic conditions to the primary
analysis. Ions were targeted for collision-induced dissociation
(CID) fragmentation on the fly based on the previously determined
accurate mass and retention time. Comparison of the structure of
the proposed compound with the fragments obtained can confirm
the identity. Accurate mass data and isotopic distributions for the
precursor and product ions can be studied and compared to
spectral data of reference compounds, if available, obtained under
identical conditions for final confirmation (HMDB, METLIN,
LIPIDMAPS). Confirmation with standards was performed by
comparison of retention time, isotopic distribution, and fragments
of commercially (Sigma) available reagents with those obtain in
real samples. All acylcarnitines (Table 3) were confirmed based on
characteristic fragments of 60.08 m/z identified as [C3H9N+H]+
and 85.03 m/z identified as [C4H5O2]
+. Lysophospholipids
(Table 4) were also confirmed with characteristic fragments of
184.07, 104.11, and 86.1 m/z for lysophosphatidylcholines (lyso
PCs), and of (M+H2141.02 m/z) for lysophosphatidylethanola-
mines (lyso PEs) as previously described [16].
Validation of the PLS-DA models
Validation of the partial least square discriminant analysis (PLS-
DA) models was performed by cross-validation using the leave 1/3
Table 2. Identification of metabolites that were significantly differentiating plasma profiles of AAA patients from controls.
Compound
RT
(min)
Measured
mass (Da)
Mass error
(ppm) Identification Change [%](p-value)
CV for
QCs [%]
A vs C S vs C A vs S
Guanidinosuccinic acid 0.7 175.056 1.1 176.064, 130.085, 118.125, 70.064,
60.056
+309 (9?10210) 216 (0.2) +388 (2?1028) 14
Hippuric acid* 1.3 179.058 21.1 180.064, 105.033, 77.04, 51.023 218 (0.04) 24 (0.8) 214 (0.4) 30
Cholanoic acid derivative 15.3 356.27 24.0 357.278, 339.262, 289.209, 275.201,
247.164, 215.176, 161.129, 135.116,
109.098, 95.085, 81.069
276 (0.03) +235 (0.2) 294 (0.0006) 21
C27 bile acid 18.2 430.306 26.5 431.31, 413.301, 395.295, 367.297,
269.19, 177.123, 149.093, 109.1, 97.063
268 (0.009) 26 (0.6) 266 (0.01) 11
Biliverdin 10.4 582.244 26.8 583.258, 523.241, 297.122, 229.162 +67 (0.2) 225 (0.1) +123 (0.02) 23
Bilirubin* 7.4 584.26 26.0 585.267, 299.138 241 (0.2) +140 (0.2) 275 (0.01) 16
Oleic acid
OR vaccenic acid
31.3 282.255 23.8 283.263, 265.251, 247.241, 240.233,
191.176, 177.162, 163.144, 149.131,
135.114, 121.1, 97.1, 83.085, 69.07, 57.07
216 (0.4) 228 (0.06) +17 (0.01) 23
Hydroxydecadienediynoic
acid
7.5 180.078 26.4 181.085, 163.075, 153.054, 139.038,
121.028, 71.049
254 (0.03) 263 (0.004) +26 (0.2) 10
N-Methylethanolamine
phosphate OR Aminopropan-
2-ol O-phosphate
0.7 155.034 22.9 156.042, 112.051, 98.917 28 (0.7) +16 (0.1) 221 (0.005) 8
Octadecatrienol 31.3 264.243 7.0 265.251, 247.241, 177.161, 163.146,
149.129, 135.117, 121.098, 109.1,
95.086, 81.069, 69.069, 57.069
28 (0.8) 259 (0.04) +122 (0.04) 16
Sphingosine-1-phosphate 15.5 379.246 7.0 380.254, 264.266, 93.068, 82.065 243 (0.002) 226 (0.008) 223 (0.06) 10
Sphinganine-1-phosphate 16.5 381.262 26.6 382.269, 284.288, 266.282 225 (0.1) 236 (0.00001) +17 (0.7) 10
PC 30.9 855.568 12.0 856.575, 797.5, 761.524, 673.508,
503.286, 444.219, 184.072, 86.096
225 (0.03) 230 (0.1) 28 (0.4) 23
A vs C - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to controls, S vs C - (+)/(2) means increased/decreased abundance in
small aneurysm group in comparison to controls, A vs S - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to small aneurysm
group. Identity of metabolites marked with asterix (*) was confirmed by analyzis of the standard.
doi:10.1371/journal.pone.0031982.t002
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out approach. The data set was divided into three parts and 1/3rd
of samples were excluded to build a model with the remaining 2/
3rd of samples. Excluded samples were then predicted by this new
model and the procedure was repeated until all samples had been
predicted at least once. Each time the percentage of correctly
classified samples was calculated.
Results
Quality control of the methodology
For quality checking, all 54 chromatograms (41 for patients/
controls plasma samples and 13 for QCs) were aligned giving
13050 features in total. A PLS-DA model (Fig. 1, panel A) was
Table 3. Identification of acylcarnitines that were significantly differentiating plasma profiles of AAA patients from controls.
Compound RT (min) Measured mass (Da) Mass error (ppm) Change [%](p-value) CV for QCs [%]
A vs C S vs C A vs S
Decanoylcarnitine 8.1 315.239 26.8 260 (0.0004) 236 (0.05) 237 (0.1) 6
Dodecanoylcarnitine 11.8 343.27 26.9 251 (0.2) 244 (0.01) 213 (0.3) 15
Tetradecenoylcarnitine 13.4 369.286 26.5 266 (0.02) 267 (0.02) +1 (NS) 6
Palmitoylcarnitine 18.5 399.332 26.7 253 (0.002) 247 (0.007) 211 (0.2) 7
Linoleylcarnitine 17.1 423.332 26.3 255 (0.0007) 241 (0.01) 224 (0.5) 7
Vaccenylcarnitine OR oleoylcarnitine 19.1 425.348 26.4 260 (0.0006) 248 (0.009) 222 (0.2) 13
Stearoylcarnitine 21.7 427.363 27.5 271 (0.05) 222 (NS) 263 (NS) 46
A vs C - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to controls, S vs C - (+)/(2) means increased/decreased abundance in
small aneurysm group in comparison to controls, A vs S - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to small aneurysm
group.
doi:10.1371/journal.pone.0031982.t003
Table 4. Identification of lysophospholipids that were significantly differentiating plasma profiles of AAA patients from controls.
Compound RT (min)
Measured mass
(Da) Mass error (ppm) Change [%](p-value) CV for QCs [%]
A vs C S vs C A vs S
Lyso PCs 21.4 479.334 7.0 245 (0.0005) 240 (0.1) 29 (0.004) 16
18.0 481.314 26.2 250 (0.0005) 215 (0.3) 240 (0.02) 8
16.4 493.314 26.4 252 (0.0005) 211 (0.5) 246 (0.002) 11
19.3 495.332 21.2 255 (0.00009) 220 (0.04) 244 (0.001) 9
22.2 507.365 7.0 255 (0.0002) +11 (0.9) 259 (0.002) 13
21.6 509.344 25.6 253 (0.0008) 221 (0.1) 235 (0.03) 30
16.5 517.313 7.0 273 (0.004) 236 (0.01) 226 (0.08) 18
17.7 519.331 23.6 261 (0.00001) 232 (0.01) 243 (0.006) 22
21.0 521.348 20.1 261 (0.00006) 225 (0.07) 248 (0.003) 19
23.7 523.361 24.9 262 (0.00005) 229 (0.02) 246 (0.002) 14
15.9 541.313 7.0 249 (0.001) 236 (0.03) 220 (0.7) 26
19.2 545.344 7.0 242 (0.005) 220 (0.2) 227 (0.06) 12
25.1 549.376 7.0 257 (0.0001) 226 (0.1) 243 (0.007) 18
18.3 567.33 24.6 245 (0.02) 240 (0.06) 29 (0.6) 42
Lyso PEs 19.6 453.283 5.0 250 (0.2) 226 (0.03) 233 (0.2) 11
18.0 477.284 22.2 264 (0.0002) 235 (0.1) 245 (0.002) 8
19.8 479.299 25.8 214 (0.0005) 28 (0.5) 249 (0.01) 9
23.8 481.314 26.2 255 (0.00007) 234 (0.005) 232 (0.03) 14
19.5 503.299 24.0 243 (0.007) 229 (0.3) 220 (0.6) 8
17.5 525.282 25.8 231 (0.007) 232 (0.002) +1 (0.9) 8
19.0 527.298 26.0 253 (0.001) 252 (0.09) 24 (0.2) 20
A vs C - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to controls, S vs C - (+)/(2) means increased/decreased abundance in
small aneurysm group in comparison to controls, A vs S - (+)/(2) means increased/decreased abundance in large aneurysm group in comparison to small aneurysm
group.
doi:10.1371/journal.pone.0031982.t004
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built for the three groups under investigation (A, S, and C) taking
all variables (without scaling) generated as molecular features in
the mass spectrum.
The robustness of the analytical procedure was tested by the
prediction of the QC samples by the model (Fig. 1, panel B).
Classification of the QCs close to the control group may be
explained by the fact, that these samples were prepared from the
pooled plasma of healthy volunteers. The quality of the model
built for two components was appropriate with variance explained
(R2= 0.852), and variance predicted (Q2= 0.369).
Samples classification
To perform sample classification, first all 41 chromatograms
were aligned giving primary dataset with 10926 features.
However, for further data treatment, only 33 samples of subjects
matching in age and sex (n = 11 in each group) were considered.
Figure 1. PLS-DA plot of plasma metabolic profiles obtained for patients and controls with prediction for QCs. n - small AAA, m –
large AAA,% – control, + - Quality control Panel A shows PLS-DA model (R2 = 0.852, Q2 = 0.369) for all samples and all variables in three groups under
investigation (A, S, and C). Panel B shows prediction for QC samples by the model obtained.
doi:10.1371/journal.pone.0031982.g001
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Primary filtering was performed by choosing the data present in a
minimum 10 samples in any group, 544 features were selected
after filtering. For those 544 features a PLS-DA model with three
groups (A, S, and C) was built (Fig. 2, panel A).
The model was validated as described in Materials and Methods
section. 1/3rd (11 samples) had to be excluded and predicted 8
times until all samples had been predicted at least once. The
percentage of samples classified correctly was calculated as
8366%. In all cases the error was either due to samples from
the small aneurysm group misclassified as C or A groups or
samples from C or A groups misclassified as S group. As patients
with small AAA were at different stages of the disease, some were
Figure 2. PLS-DA plot of plasma metabolic profiles obtained for age matched aneurysm patients and controls. n - small AAA, m –
large AAA, + - predicted AAA samples not matching in age Panel A shows PLS-DA model (R2 = 0.835, Q2 = 0.335) for plasma samples obtained from
patients and controls matching in age (n = 11). Panel B shows prediction for additional samples of patients (4 with large and 4 with small AAA).
Sample marked by the circle was obtained from the patient with AAA size of 5.4 cm, and was assigned to large AAA group because the patient was
operated on.
doi:10.1371/journal.pone.0031982.g002
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at an early stage and others at more advanced stage, misclassi-
fication connected with this group was strongly possible and does
not decrease the validity of the study.
Eight samples from AAA patients that were excluded from the
previous model to avoid age mismatch were then predicted by
using 544 features selected after primary filtering. As it can be seen
on Figure 2, panel B, all samples of patients with small AAA and
three samples of patients with large AAA were perfectly classified
by the model. Only one sample of a patient with large AAA was
classified between A and S groups. Interestingly, after checking the
medical records, this patient was found to have the smallest size of
AAA among patients in A group (5.4 cm) and was assigned by the
medical group to large AAA because the patient was operated on.
To select metabolites that change between groups with
statistical significance, first variables underwent secondary filtering
to select features present in a minimum of 10 samples per group for
each comparison separately. Then an unpaired t test was
performed for log-transformed intensities for comparisons of C
vs A, C vs S, and A vs S giving 104, 47, and 61 features with
p#0.05 in each comparison respectively. Identification of
statistically significant metabolites was performed as described in
Materials and Methods section. Identified metabolites are summa-
rized in Tables 2, 3 and 4 including retention time, the mass
obtained in the LC-QTOF system and the mass error when
comparing with the database. In addition the percentage of
change between the groups in the comparisons performed, MS/
MS fragments (Table 2), and the coefficients of variation for the
abundances of these compounds in QCs (CV) are also shown in
the tables.
Prediction for small AAA
In addition to the previous model, we wanted to check the
ability to predict small aneurysm in a model built for large
aneurysms and controls. A PLS-DA model (Fig. 3, panel A) for two
groups (A and C) was built for masses after primary filtering (544
variables) and validated as described in Materials and Methods
section. 1/3rd (7 samples) had to be excluded and predicted 7 times
until all samples had been predicted at least once. Samples
excluded were always perfectly predicted by the model (100%
samples classified correctly).
15 samples of patients with small AAA were then predicted in
that model. As it can be seen on Figure 3, panel B, samples of
patients with small AAA are classified between controls and large
AAA.
These results suggest that there was a clear pattern of
metabolites that were detected in the LC-MS plasma fingerprints
that need to be investigated.
Discussion
In the present study some metabolites were detected as
significantly altered in plasma, previously found [13] to be
released by normal and pathological wall arteries or intraluminal
thrombus (ILT) to a culture medium (Table 2). Among them
guanidinosuccinic acid (GSA), which was mainly released by the
luminal part of ILT, has been found highly increased in the plasma
of patients from A group in comparison to controls. GSA, which
mimics nitric oxide in terms of its vasodilatory action and its ability
to activate the NO generating N-methyl-D-aspartate (NMDA)
receptor [17], is probably generated in ILT, secreted to blood
stream, and the amount of secreted GSA is related to the stage of
AAA. Hippuric acid, which was secreted only by the luminal part
of ILT, was found significantly decreased in plasma in group A
compared to controls. This observation could correlate to the
hyperexcretion of hippuric acid in atherosclerotic state, previously
found to be increased in the urine of atherosclerotic rats compared
to control group [18]. Other metabolites, like oleamide, stearic
acid, docosahexaenoic acid, and alpha-tocopherol were also found
to discriminate the plasma of AAA patients from controls, however
with significance higher than 0.05 (data not shown).
In the group of other metabolites significantly discriminating
the plasma of patients with large aneurysm, small aneurysm, and
controls, two (cholanoic acid derivative and bile acid) are
metabolites of cholesterol. Decreased levels of those metabolites
were observed in plasma of patients from A as well as from S
group in comparison to controls. As cholesterol is slightly soluble
in water, in plasma it is mainly transported within low-density
lipoproteins (LDL) and high-density lipoproteins (HDL). We have
also found changes in haemoglobin metabolites (bilirubin,
biliverdin). Free haemoglobin could be released to blood stream
by haemoaglutination of red blood cells in luminal part of ILT
[7].
Long-chain acylcarnitines are decreased in the plasma of
aneurysm patients compared to controls. There was a clear
decreasing trend with increasing size of aneurysm (Table 3), which
may indicate altered fatty acid b-oxidation or deficiency of
carnitine. Carnitine is the requisite carrier of activated long-chain
fatty acids from cytoplasmic compartment into mitochondria
where b-oxidation enzymes are located. There is a significant body
of evidence, that carnitine deficiency is associated with many forms
of cardiovascular disorders [19,20], in a study with hypercholes-
terolaemic rabbits [19] it was shown, that treatment with L-
carnitine completely prevented the progression of atherosclerotic
lesions. As can be seen in Table 2, a significant decrease in
sphingosine 1-phosphate (S1P) and sphinganine-1-phosphate in
AAA patients can be found. Both molecules are sphingolipids;
sphinganine-1-phosphate is a parent of sphingosine and S1P.
Sphingolipids have been suggested to be agonists of peroxisome
proliferator-activated receptors (PPARs) [21,22], which regulate
the expression of genes involved in fatty acid b-oxidation and are
major regulators of energy homeostasis [23]. The role of PPARa
and PPARc receptors in inflammation and atherosclerosis has
been already described, and it is suggested, that PPARs activation
regulates various targets that should decrease atherosclerosis,
inflammation, and their complications [24–26]. Moreover, it was
demonstrated, that loss of PPARc in vascular SMCs promotes
AAA in a vascular SMC-selective PPARc knockout mice model
[27]. In addition, S1P was proved to induce vasocontraction in the
canine basilar artery in vitro and in vivo, possibly through a
mechanism involving activation of the Rho/Rho-kinase pathway
[28]. S1P is a lysophospholipid and significant changes in other
lysophospholipids like LysoPEs and LysoPCs are reported in this
investigation (Table 4). For those metabolites, similar changes to
long-chain acylcarnitines were obserbed, i.e. lower concentrations
in plasma of patients compared to controls with clear trend to
decrease with increasing aneurysm size. The possible explanation
for decrease in the amount of LysoPCs/PEs in plasma of AAA
patients with a trend related to the size of aneurysm is their
accumulation in the ILT. Moreover, in a previous study [13]
increased release of LysoPCs by abluminal in comparison to
luminal part of ILT was observed. Lysophospholipids are products
of the action of phospholipase A2 (PLA2), enzyme hydrolysing
phospholipids to free fatty acids, eicosanoids and lysophospholi-
pids. Interestingly, in a very recent report [29] authors showed an
increased activity of PLA2 in serum of AAA patients. Eicosanoids
and lysophospholipids are very important signaling molecules
[30,31], therefore, increased activity of PLA2 reported by
Golledge et al. [29] could be a respond of the body in order to
Metabolomics in Aortic Abdominal Aneurysm
PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31982
augment low level of lysophospholipids in plasma of AAA patients
observed in the present study.
Conclusion
The results presented here reveal, that LC-QTOF-MS based
metabolic fingerprinting of plasma from patients with AAA is a
very good technique to distinguish between small AAA, large
AAA, and controls which can have a clinical interest. With the use
of a validated PLS-DA model it was possible to classify patients
according to the stage of the aneurysm and predict properly the
stage of AAA of additional patients. Most of metabolites identified
in this study were significantly different in the comparison of small
AAA with controls, and the tendency to increase the percentage of
change and significance with the size of aneurysm. Therefore,
identified metabolites could be good targets for the early detection
of AAA. These metabolites indicate a role for cholesterol
Figure 3. PLS-DA plot of plasma metabolic profiles obtained for age matched large aneurysm patients and controls.n - small AAA,m
– large AAA, % – control Panel A shows PLS-DA model (R2 = 0.977, Q2 = 0.817) for plasma samples obtained from patients with large AAA and
controls matching in age (n = 11). Panel B shows prediction for all samples of small AAA patients.
doi:10.1371/journal.pone.0031982.g003
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metabolism, carnitine and fatty acid b-oxidation in the develop-
ment and progression of AAA. Moreover, increased concentra-
tions of sphingolipids observed in the plasma of AAA patients may
be responsible for AAA pathogenesis as agonists of the PPAR
receptors, and loss of PPARc in vascular SMCs was found to
promote AAA. However, further investigations combining LC-MS
with other techniques used in metabolomics like GC-MS or NMR,
performed on a bigger population, as well as target analysis of
guanidinosuccinic acid with LC-QqQ-MS are necessary to
confirm these results and be able to use them as clinical markers.
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